Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
FTSE 250 movers: Hikma, Rotork shine, Renishaw slips
(Sharecast News) - FTSE 250: 19,373.11 +0.65%. Specialist engineer Rotork said it expected adjusted operating profit to be slightly ahead of expectations driven by strong order intake.
Sales for the three months to April 2 rose 18% against a more supply-chain disrupted comparative period and benefited from both volume and selling price increases, with all divisions and regions ahead year-on-year and with particularly strong growth in the Americas, the company said on Friday.
Order intake was ahead a mid-teen percentage year-on-year on an organic constant currency basis, with all divisions making "encouraging progress", Rotork said.
"Our orders continue to be driven largely by customers' operational spend. In addition, in the period we saw a return of a relatively high level of large project activity."
"The outlook for our end markets remains positive and our record order book gives us good visibility into the second half of the year. We are encouraged by the early momentum we are seeing with our growth+ strategy and are investing in the programme as planned. Whilst we are cognisant of the continuing global macro-economic uncertainty, we now expect 2023 adjusted operating profit to be slightly ahead of our earlier expectations."
Hikma Pharmaceuticals upgraded full-year guidance after a stronger-than-expected start to the year for its generics business but expressed concern about the impact of the current conflict in Sudan on operations.
"The safety and wellbeing of our colleagues in Sudan is a top priority and we are doing what we can to support them. Our current guidance does not take into account any potential impact this evolving situation could have on our business. In 2022 sales from Sudan in our branded and injectables businesses represented 2.5% of group revenue," the company said on Friday.
"We have also had a stronger than expected start in our generics business, leading us to upgrade our guidance for the full year."
Renishaw downgraded its full-year outlook on Friday amid lower demand from the semiconductor and electronics sectors.
The company said it now expects full-year revenues of between £680m and £700m, and adjusted pre-tax profit of £135m and £150m. This is down from previous guidance for revenues of £690m to £730m and adjusted pre-tax profit of between £140m and £165m.
In an update for the nine months to the end of March, Renishaw said total revenue rose 6% on the same period a year earlier to £492.4m, while adjusted pre-tax profit fell 10% to £111.8m.
Revenue in the manufacturing technologies segment increased 6% to £496.7m, while revenue in analytical instruments and medical devices was just 1% higher at £25.3m.
Renishaw said: "We expect current market conditions to continue during the remainder of this financial year. We continue to invest in innovative new products and manufacturing capacity to support our growth objectives, whilst managing costs carefully and focusing on productivity."
At 1450 BST, the shares were down 3% at 3,560p.
Jefferies reiterated its 'underperform' rating on the shares after the update. It said: "We believe that market expectations were set low, so this downgrade may not come as a major surprise.
"Our view, however, is that market conditions will continue through the remainder of calendar 2023, and therefore we see DD downgrade risk to FY24F estimates as well, which will pressure the share price."
FTSE 250 - Risers
Rotork (ROR) 327.60p +3.74%
Hikma Pharmaceuticals (HIK) 1,834.50p +3.64%
Bakkavor Group (BAKK) 99.00p +3.56%
Rathbones Group (RAT) 1,962.00p +3.15%
Genuit Group (GEN) 300.00p +3.09%
CLS Holdings (CLI) 134.40p +3.07%
Urban Logistics Reit (SHED) 140.40p +2.78%
Dr. Martens (DOCS) 167.30p +2.64%
Crest Nicholson Holdings (CRST) 268.00p +2.52%
Redrow (RDW) 521.00p +2.46%
FTSE 250 - Fallers
W.A.G Payment Solutions (WPS) 95.20p -7.12%
Renishaw (RSW) 3,554.00p -3.42%
Petershill Partners (PHLL) 163.60p -2.50%
Caledonia Investments (CLDN) 3,525.00p -2.22%
Telecom Plus (TEP) 1,824.00p -2.15%
Bank of Georgia Group (BGEO) 2,975.00p -1.98%
Syncona Limited NPV (SYNC) 155.60p -1.39%
Abrdn Private Equity Opportunities Trust (APEO) 446.00p -1.33%
Drax Group (DRX) 625.20p -1.23%
4Imprint Group (FOUR) 4,525.00p -1.20%
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.